Global Biosimilars Partnership Report / Directory 2021: Access Conditions and Agreements for Over 170 Offers 2010-2021 –

DUBLIN – (BUSINESS WIRE) – The report “Global Biosimilars Partnering Terms and Agreements 2010 to 2021” has been added to offer.

The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the biosimilars agreements and partnership agreements entered into by the world’s leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter into partnership agreements with biosimilars. The majority of agreements are at an early stage of development where the licensee obtains a right or option right to license the biosimilar technology or product candidates from the licensor. These agreements tend to be multi-component, starting with collaborative R&D and the commercialization of results.

Understanding the flexibility of the terms of the agreements negotiated by a potential partner provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of the terms. While many small businesses will be looking for details on payment terms, the devil is in the details of triggering payments – contract documents provide that insight where press releases and databases do not. .

This report contains links to online copies of actual biosimilar offerings and contractual documents as submitted to the Securities Exchange Commission by the companies and their partners. Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.

Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.

In addition, a comprehensive appendix is ​​provided, curated by biosimilar partner company AZ, transaction type definitions and examples of biosimilar partnership agreements. Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contractual document, providing easy access to each contractual document on demand.

The report also includes numerous tables and figures that illustrate trends and biosimilar partnership and negotiation activities since 2010.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of biosimilar technologies and products.

Scope of the report

The terms and global partnership agreements for biosimilars 2010 to 2021 include:

  • Trends in biosimilar transactions in the biopharmaceutical industry since 2010

  • Access to title, advance, milestone and royalty data

  • Access to more than 170 transaction files and contractual documents on biosimilars, where applicable

  • The main biosimilar offers by value since 2010

  • The most active biosimilars negotiators since 2010

  • The main partnership resources for biosimilars

In Global Biosimilars Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

  • Company from A to Z

  • Title value

  • Stage of development at signing

  • Component type of the agreement

  • Specific therapeutic and technological target

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in the negotiation of biosimilars

2.1. introduction

2.2. Biosimilar partnerships over the years

2.3. The most active biosimilars negotiators

2.4. Biosimilar partnerships by type of agreement

2.5. Biosimilar partnership by therapeutic area

2.6. Terms of the agreement for the biosimilar partnership

2.6.1 Key values ​​of the partnership on biosimilars

2.6.2 Biosimilars Process Upfront Payments

2.6.3 Milestone Payments for Biosimilars

2.6.4 Biosimilar royalty rate

Chapter 3 – Best Biosimilar Offers

3.1. introduction

3.2. Best Biosimilar Deals By Value

Chapter 4 – The Most Active Biosimilars Negotiators

4.1. introduction

4.2. The most active biosimilars negotiators

4.3. Profiles of the most active biosimilar partner companies

Chapter 5 – Negotiation directory for biosimilars contracts

5.1. introduction

5.2. Directory of biosimilar contracts

Chapter 6 – Biosimilar Transactions by Type of Technology

Chapter 7 – Partner Resource Center

7.1. Online partnership

7.2. Partnership events

7.3. Further reading on negotiation


Annex 1 – Biosimilar offers by AZ company

Annex 2 – Biosimilar offers by stage of development

Annex 3 – Biosimilar offers by type of offer

Annex 4 – Biosimilar offers by therapeutic area

Annex 5 – Definitions of types of transactions

Companies mentioned

  • BeiGene

  • Momenta Pharmaceuticals

  • Ewopharma

  • Samsung Bioepis

  • Biotechnology compass

  • YL organic products

  • alvogen

  • Simcere Pharma

  • Medicago

  • Cipla

  • Merck serono

  • JAMP Pharma Group

  • Yoshindo

  • SQI diagnosis

  • R-Pharm

  • Sandoz

  • ProBioGen

  • Diabeloop

  • Biocnd

  • Epirus Biopharmaceuticals

  • mAbXience

  • AIT Biosciences

  • Concord Biosciences

  • Abreos Biosciences

  • Revance Therapeutics

  • Walter and Eliza Hall Institute

  • Zhejiang Hisun Pharmaceutical

  • TS Dyne

  • Amneal Pharmaceuticals

  • MGC diagnosis

  • Theradiag

  • XL-Protein

  • Aceno Biotherapeutics

  • Baxter International

  • Zhejiang Huahai Pharmaceutical

  • BioXpress

  • Pharma Holdings algorithm

  • World-class research

  • PharmaPraxis

  • GC Pharma

  • Universal cells

  • Synthon

  • Chimio Sa Lugano

  • Amgen

  • Return-To-Line

  • Vela Laboratories

  • NeuClone

  • Cellectis

  • TR-Pharm

For more information on this report, visit


Laura Wood, Senior Press Director
For EST office hours, call 1-917-300-0470

For USA / CAN call toll free 1-800-526-8630

For GMT office hours, call + 353-1-416-8900

Comments are closed.